Brokerage firm H.C. Wainwright Assumes its rating on RXi Pharmaceuticals Corp(NASDAQ:RXII). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Jun 7, 2016.
RXi Pharmaceuticals Corp (RXII) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -3.24% at a volume of 27,848. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.16. The peak price level was also seen at $2.16 while the days lowest was $2.08. Finally the shares closed at $2.09. The 52-week high of the shares is $2.9 while the 52-week low is $0.25. According to the latest information available, the market cap of the company is $14 M.
RXi Pharmaceuticals Corp(RXII) last announced its earnings results on May 12, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.34. Analysts had estimated an EPS of $-0.45.
Several Insider Transactions has been reported to the SEC. On Apr 2, 2015, Geert Cauwenbergh (CEO) purchased 5,000 shares at $0.72 per share price.Also, On Jan 23, 2015, Robert J Bitterman (director) purchased 5,000 shares at $1.20 per share price.
RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs primarily in the areas of dermatology and ophthalmology. The Company’s development programs are based on its siRNA technology and immunotherapy agents. Its clinical development programs include self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent Samcyprone for the treatment of such disorders as alopecia areata warts and cutaneous metastases of melanoma. In addition to these clinical programs the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas as well as in other areas of interest.